Your browser doesn't support javascript.
loading
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller, Tobias; Münnich, Ira A; Windisch, Roland; Hilger, Patricia; Schewe, Denis M; Humpe, Andreas; Kellner, Christian.
Afiliação
  • Zeller T; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
  • Münnich IA; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
  • Windisch R; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
  • Hilger P; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
  • Schewe DM; Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
  • Humpe A; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
  • Kellner C; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Front Immunol ; 14: 1240275, 2023.
Article em En | MEDLINE | ID: mdl-37781391
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article